These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 822863)

  • 1. Oral vaccination against Porteus mirabilis.
    Jones RJ
    Br J Exp Pathol; 1976 Aug; 57(4):395-9. PubMed ID: 822863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against Gram-negative infection by 'super-active' antigen.
    Roe EA
    Immunology; 1976 Nov; 31(5):707-15. PubMed ID: 825449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascending to a UTI vaccine?
    Clarkson S
    Nat Rev Microbiol; 2004 Feb; 2(2):90. PubMed ID: 15040255
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccination to Protect Against Proteus mirabilis Challenge Utilizing the Ascending Model of Urinary Tract Infection.
    Smith SN; Himpsl SD; Mobley HLT
    Methods Mol Biol; 2019; 2021():201-215. PubMed ID: 31309507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
    Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P
    Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice.
    Scavone P; Miyoshi A; Rial A; Chabalgoity A; Langella P; Azevedo V; Zunino P
    Microbes Infect; 2007 Jun; 9(7):821-8. PubMed ID: 17540603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Taishan Pinus massoniana pollen polysaccharide on the subunit vaccine of Proteus mirabilis in birds.
    Cui G; Zhong S; Yang S; Zuo X; Liang M; Sun J; Liu J; Zhu R
    Int J Biol Macromol; 2013 May; 56():94-8. PubMed ID: 23403027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Protective effect of coli-proteus vaccine in an experimental animal model].
    Bĕlohlávek S; Konícková L
    Cesk Farm; 1980 May; 29(3-4):95-9. PubMed ID: 6996844
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
    Li X; Lockatell CV; Johnson DE; Lane MC; Warren JW; Mobley HL
    Infect Immun; 2004 Jan; 72(1):66-75. PubMed ID: 14688082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
    Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
    Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aerosol immunization with RE 595 Salmonella minnesota on lung bactericidal activity against Serratia marcescens, Enterobacter cloacae, and Pseudomonas aeruginosa.
    LaForce FM
    Am Rev Respir Dis; 1977 Aug; 116(2):241-9. PubMed ID: 407823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vaccination and multivalent vaccine against Pseudomonas aeruginosa keratitis.
    Gerke JR; Nelson JS
    Invest Ophthalmol Vis Sci; 1977 Jan; 16(1):76-80. PubMed ID: 832968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An oral enteritis-vaccine composed of twelve heat-inactivated Enterobacteriaceae 3. Communication: studies on efficacy tests in mice protection tests (author's transl)].
    Raettig H
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981 Nov; 250(4):511-20. PubMed ID: 7036591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Protective properties of antigenic complexes of Proteus].
    Kreĭnin LS; Kaverina KG; Aksenova EV; Buatkova LIu
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Jan; (1):60-4. PubMed ID: 7015763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-protection of mice provided by active and passive immunization against experimental infections with virulent Proteus rettgeri and Providencia bacteria.
    Penner JL; Whiteley GR
    Infect Immun; 1978 May; 20(2):347-51. PubMed ID: 669801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse model.
    Moayeri N; Collins CM; O'Hanley P
    Infect Immun; 1991 Oct; 59(10):3778-86. PubMed ID: 1894376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins.
    Scavone P; Sosa V; Pellegrino R; Galvalisi U; Zunino P
    Microbes Infect; 2004 Jul; 6(9):853-60. PubMed ID: 15374007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the immune enhancement of intrapulmonary bactericidal mechanisms.
    Jakab GJ
    Infect Immun; 1976 Aug; 14(2):389-98. PubMed ID: 9364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.